Securities fraud litigation history and active cases
In Litigation
0
Settlement
0
Closed
2
Total Settlement
$45M
4:21cv987 • December 20, 2021
Class Period Start
November 14, 2016
Class Period End
June 20, 2022
PSLRA Deadline
February 18, 2022
Case Allegations
10b5 + Sec11
10b-5 Statutes of Repose
Nov 14, 2019
Sec11 Statutes of Repose
Nov 14, 2022
Country
United States
Court
Federal Court
Please note that for cases in the settlement stage, claims are handled by the claims administrator and NOT Levi & Korsinsky. Any information or documentation previously provided to us does not constitute submission of a claim. If you need to file a claim, check the status of a claim, or have questions regarding distribution of settlement funds, please contact the claims administrator below.
Claim Deadline
April 24, 2024
Settlement Fund
$45,000,000
Settlement Status
Disbursed
Settlement Class
All persons or entities that purchased or otherwise acquired during the period between November 14, 2016 and December 8, 2021, inclusive, you purchased or otherwise acquired the common stock of Reata Pharmaceuticals, Inc. (“Reata” or the “Company”), including Reata common stock purchased or otherwise acquired pursuant and/or traceable to Reata’s 2019 Offering and/or 2020 Offering
Claim Administrator
Epiq
Doyle v. Reata Pharmaceuticals, Inc.
c/o Epiq
P.O. Box 5566
Portland, OR 97228-5566
+1 877-664-7398
[email protected]
Settlement Website
https://www.reatasecuritieslitigation.com/Hearing Date
March 29, 2024
Opt-out Deadline
March 8, 2024
Settlement Note
Download hereProof Of Claim
Download here
Jan 3, 2025
Disbursement Approved
The court has approved the distribution of settlement funds to eligible class members. Investors with approved claims may receive payments from the settlement. If you have questions about your claim or payment, contact the claims administrator.
Mar 29, 2024
Final Approval of Settlement
The court has granted final approval of the settlement. Eligible investors who submit valid claims may receive a payment once the claims review and distribution process is completed.
Dec 26, 2023
Proof of Claim Form
To receive your portion of the recovery (if you are eligible), you must submit this form to the claims administrator by the deadline indicated on the form itself. If you do not submit this form in time, you will not be entitled to compensation. If you have questions about how to complete the form, you should contact the claims administrator.
Nov 27, 2023
Preliminary Approval of Settlement
The court has granted preliminary approval of a proposed settlement. This means the settlement can move forward for further consideration, but it has not yet received final approval. Potential class members will generally receive notice explaining the settlement, their rights, and any deadlines for submitting a claim, objecting to the settlement, or choosing not to participate.
Nov 3, 2023
Proposed Settlement
4:20cv796 • October 15, 2020
Class Period Start
October 15, 2019
Class Period End
August 7, 2020
PSLRA Deadline
December 14, 2020
Case Allegations
10b5
Statutes of Repose
Oct 15, 2022
Country
United States
Court
Federal Court
Sep 27, 2021
Voluntary Dismissal
The plaintiff in this action has chosen not to proceed with the case. Once a case is voluntary dismissed, the courts will usually close the case and no further action will be taken.
Aug 10, 2021
Scheduling Order
Jul 15, 2021
Appointment of Lead Plaintiff
The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.
Oct 15, 2020
First Filed Complaint
A securities fraud class action complaint has been filed on behalf of certain investors in REATA PHARMACEUTICALS INC.
TOP
